Media stories about Versartis (NASDAQ:VSAR) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Versartis earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.9272648103559 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

A number of equities analysts have weighed in on VSAR shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $4.00 price target (up previously from $3.00) on shares of Versartis in a research note on Friday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $14.00 price target (down previously from $34.00) on shares of Versartis in a research note on Friday, September 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $26.00 price target on shares of Versartis in a research note on Friday, September 8th. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Cowen and Company downgraded shares of Versartis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $45.00 to $3.00 in a research note on Friday, September 22nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $7.22.

Versartis (NASDAQ:VSAR) traded down $0.05 during trading on Tuesday, hitting $1.70. 560,573 shares of the stock traded hands, compared to its average volume of 2,190,000. Versartis has a 52 week low of $1.70 and a 52 week high of $24.00. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.09.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.78). During the same period last year, the business posted ($0.92) EPS. research analysts anticipate that Versartis will post -4.06 EPS for the current fiscal year.

In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 2,132,769 shares of company stock worth $7,014,761. Company insiders own 10.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.